Anulex Technologies, Inc. Appoints Richard Lunsford as President and Chief Executive Officer

MINNEAPOLIS--(BUSINESS WIRE)--Anulex Technologies, Inc., a privately held medical device manufacturer focusing on spinal disc Preservation and Anular Repair ™ products, today announced that the Company’s Board of Directors has appointed Richard Lunsford as President and Chief Executive Officer and the Company’s shareholders have elected him to the Board of Directors. Michael McCormick, the previous CEO has resigned to pursue other interests. Mr. Lunsford brings decades of senior management experience in the development and commercialization of innovative medical devices. Anulex has obtained United States Food and Drug Administration clearance for its Inclose and Xclose soft tissue repair products and is commercializing these products in the United States.

“We are delighted by the addition of Rich to the Anulex team. Rich has a proven track record in the medical device industry and brings demonstrated entrepreneurial leadership to Anulex as we continue our commercial rollout”

“We are delighted by the addition of Rich to the Anulex team. Rich has a proven track record in the medical device industry and brings demonstrated entrepreneurial leadership to Anulex as we continue our commercial rollout”, said Dave Stassen, Managing Director of Split Rock Partners and Anulex Board member.

Mr. Lunsford has more than 24 years of leadership experience in the medical device field. Most recently, he served as Senior Vice President and President of United States Commercial Operations at ev3, Inc. (Nasdaq: EVVV), where he led the commercial operations for ev3’s domestic business. Previous to ev3, he was President and CEO of Acorn Cardiovascular, Inc. Over the course of his career, Mr. Lunsford has held positions of President, Sulzer Medica / SpineTech and Vice President, Worldwide Sales SpineTech and Director of Corporate Sales, SciMed Life Systems / Boston Scientific Corporation.

About Anulex

Anulex Technologies, Inc. is a privately held company dedicated to the development and commercialization of unique and proprietary soft tissue repair products with primary interests in treatments for the soft tissues of the spine. Back injuries afflict four out of every five individuals at some point during their life, and it is a major cause of disability. Xclose, Inclose and Anulex are registered trademarks of Anulex Technologies, Inc. in the United States. More information on the Company can be found at www.anulex.com.